Fusion Antibodies plc
FAB.L · LSE
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | £359 | £1,199 | £195 | £2,049 |
| Short-Term Investments | £0 | £0 | £0 | £0 |
| Receivables | £332 | £557 | £953 | £1,648 |
| Inventory | £269 | £460 | £539 | £585 |
| Other Curr. Assets | £300 | £46 | £0 | £0 |
| Total Curr. Assets | £1,260 | £2,262 | £1,687 | £4,282 |
| Property Plant & Equip (Net) | £63 | £158 | £375 | £633 |
| Goodwill | £0 | £0 | £0 | £0 |
| Intangibles | £0 | £0 | £0 | £0 |
| Long-Term Investments | £0 | £0 | £0 | £0 |
| Tax Assets | £0 | £0 | £0 | £0 |
| Other NC Assets | £0 | £0 | £0 | £0 |
| Total NC Assets | £63 | £158 | £375 | £633 |
| Other Assets | £0 | £0 | £0 | £0 |
| Total Assets | £1,323 | £2,420 | £2,062 | £4,915 |
| Liabilities | – | – | – | – |
| Payables | £372 | £283 | £480 | £466 |
| Short-Term Debt | £40 | £40 | £70 | £132 |
| Tax Payable | £0 | £43 | £136 | £68 |
| Deferred Revenue | £0 | £0 | £0 | £0 |
| Other Curr. Liab. | £211 | £218 | £193 | £542 |
| Total Curr. Liab. | £623 | £584 | £879 | £1,208 |
| LT Debt | £0 | £23 | £40 | £3 |
| Deferred Rev, NC | £0 | £0 | £0 | £0 |
| Deferred Tax Liab, NC | £0 | £0 | £0 | £0 |
| Other NC Liab. | £31 | £20 | £20 | £20 |
| Total NC Liab. | £31 | £43 | £60 | £23 |
| Other Liabilities | £0 | £0 | £0 | £0 |
| Cap. Leases | £20 | £43 | £75 | £69 |
| Total Liabilities | £654 | £627 | £939 | £1,231 |
| Equity | – | – | – | – |
| Pref Stock | £0 | £0 | £0 | £0 |
| Common Stock | £4,197 | £3,815 | £1,040 | £1,040 |
| Retained Earnings | -£11,467 | -£9,765 | -£7,564 | -£5,003 |
| AOCI | £0 | £0 | £0 | £0 |
| Other Equity | £7,939 | £7,743 | £7,647 | £7,647 |
| Total Equity | £669 | £1,793 | £1,123 | £3,684 |
| Supplemental Information | – | – | – | – |
| Minority Interest | £0 | £0 | £0 | £0 |
| Total Liab. & Tot. Equity | £1,323 | £2,420 | £2,062 | £4,915 |
| Net Debt | -£319 | -£1,136 | -£85 | -£1,914 |